McCormick Place Chicago, IL, USA

Day-by-day guide to ASCO

1-5 June 2007

McCormick PlaceChicago, IL, USA

HLR42220_ASCO_PocketPlanner 21/5/07 18:22

HLR42220_ASCO_PocketPlanner 21/5/07 18:22 Page 4

Contents

Congress details

Dining

Safety

Congress site plan

Key

Saturday 2 June

Sunday 3 June

Monday 4 June

Tuesday 5 June

Hotels

Map 31

30

28

24

19

12

11

6

4

3

2


2

Congress details

Congress venue

McCormick Place2301 South Lake Shore DriveChicago, IL 60616, USATel: 312 791 7000; Fax: 312 791 6543

Congress registration

Location: McCormick PlaceFriday 1 June: Onsite registration opens

(including self-registration)Tuesday 5 June: Onsite registration closes

Congress dates and opening hours

Friday 1 June 13:00-18:00Saturday 2 June 07:30-18:00Sunday 3 June 07:30-18:00Monday 4 June 07:30-18:00Tuesday 5 June 07:30-12:45


3

Dining

Recommended restaurants

Aria (American Contemporary with International Flair)200 North Columbus Drive, Chicago, IL 60601Tel: 312 444 9494

Bandera (American Contemporary)535 North Michigan Avenue, Chicago, IL 60611Tel: 312 644 3524

Catch 35 (Seafood)35 West Wacker Drive, Chicago, IL 60601Tel: 312 346 3500

China Grill (Pan-Asian)230 North Michigan Avenue, Chicago, IL 60601Tel: 312 334 6700

Kevin (French Fusion)9 West Hubbard Street, Chicago, IL 60610Tel: 312 595 0055

McCormick & Schmick’s (Seafood)1 East Wacker Drive, Chicago, IL 60601Tel: 312 923 7226

Morton’s (Steak and Seafood)65 East Wacker Place, Chicago, IL 60601Tel: 312 201 0410

Phil Stefani’s 437 Rush (Italian Steakhouse)437 North Rush Street, Chicago, IL 60611Tel: 312 222 0101

Shula’s Steakhouse (Steak and Seafood)301 East North Water Street, Chicago, IL 60611Tel: 312 670 0788

The Palm (Steak, Seafood and Italian)323 East Wacker Drive, Chicago IL 60601Tel: 312 616 1000

Vermilion (Indian/Latin Fusion)10 West Hubbard Street, Chicago, IL 60610Tel: 312 527 4060

Volare (Italian)201 East Grand Avenue, Chicago, IL 60611Tel: 312 410 9900


4

Safety

Safety tips

On leaving the congress site you are advised to remove your ASCO name badge or any Roche identity insignia

Keep jewellery or accessories to a minimum and do not displaycameras or bags that can draw attention

Keep your wallet or precious belongings in your inside front pocket orwear your handbag across your shoulders

Sightsee on well-lit, well-travelled streets and passages either with acolleague or in a group

Important telephone numbers

Emergency services (Police, Ambulance, Fire): 911Non-emergency services (Police and City Services): 311Yellow Cab Chicago: 312 8294 222Chicago Office of Tourism: 312 744 2400


5


6

Congress site plan


7


8

Floor plans

Lakeside Center

North Building

Level 3Exhibition Halls Meeting Rooms (E350–E354)Arie Crown Balcony

Level 3Exhibition Halls

Level 2Meeting Rooms (N226–N231)

Level 4Meeting Rooms (N426–N427)

Level 1Exhibition Halls Meeting Rooms (N126–N140)

Level 2Exhibition HallsMeeting Rooms (E250–E272)Arie Crown Theater

Level 1Offices

Level 4Meeting Rooms (E450–E451)

Arie Crown Theater


9

South Building

West Building

Level 5Rooftop Garden

Level 4Meeting Rooms

Level 3BallroomExhibition Hall

Level 2Food Court/RestaurantShops & Services

Level 1Central Transportation CenterMeeting Rooms

Level 3Exhibition HallsGrand Concourse

Level 2Food Court/RestaurantShops & ServicesMetra Trains

Level 1Grand Ballroom (S100)Meeting Rooms (S101–S106)

Level 4Vista Room (S406)Meeting Rooms (S401–S405)

Level 5Meeting Rooms (S501–S505)


10


11

Key

Key to symbols used throughout the planner

Avastin

Bondronat

Herceptin

MabThera

Tarceva

XelodaX

T

M

H

B

A


12

POSTER DICUSSION SESSION

Time: 08:00-12:00 [discussion 12:00-13:00]Venue: S403 [S406 Vista Room]

Breast cancer - metastatic

HER2 gene amplification (HER2) and hormone receptor

expression (ER/PR) in early (EBC) and metastatic breast

cancer (MBC) in the same patients (U Wilking; Poster 10,

Abstract 1023)

A quality-adjusted time without symptoms or toxicity

(Q-TWiST) analysis comparing lapatinib plus capecitabine

compared to capecitabine for metastatic breast cancer

(MBC) (B Sherrill; Poster 13, Abstract 1026)

A randomized trial of capecitabine (C) given intermittently

(IC) rather than continuously (CC) compared to classical

CMF as first-line chemotherapy for advanced breast cancer

(ABC) (M Stockler; Poster 18, Abstract 1031)

Lapatinib (L) plus capecitabine (C) in HER2+ advanced

breast cancer (ABC): Genomic and updated efficacy data

(CE Geyer; Poster 22, Abstract 1035)

GENERAL POSTER SESSION

Time: 08:00-12:00Venue: S Hall A2

Health services research

Cost-effectiveness of rituximab plus CVP for first-line

treatment of advanced indolent lymphoma (J Hornberger;

Poster D13, Abstract 6583)

The utilization of new oncology drugs: A global perspective

(B Jönsson; Poster F14, Abstract 6612)

Cost-effectiveness (CE) analysis of CHOP and rituximab for

diffuse large B-cell lymphoma (DLBCL) in British Columbia

(BC) (GW Loh; Poster G11, Abstract 6623)

M

M

X

X

X

Saturday

2 June

Xeloda MabTheraMX


13



Lymphoma and plasma cell disorders

Rituximab maintenance therapy (RM) for

relapsed/refractory follicular lymphoma (FL): Long-term

economic impact in the French setting (P Brice; Poster X5,

Abstract 8076)

A phase IB safety and pharmacokinetic (PK) study of

recombinant human Apo2L/TRAIL in combination with

rituximab in patients with low-grade non-Hodgkin

lymphoma (L Yee; Poster X7, Abstract 8078)

Cost-effectiveness of rituximab maintenance therapy for

patients with follicular lymphoma: The Spanish perspective

(J Gómez Codina; Poster Z7, Abstract 8092)

ORAL ABSTRACT PRESENTATION SESSION

Time: 13:00-16:00Venue: E Arie Crown Theater

Leukemia, myelodysplasia and transplantation

Seventy percent of complete responders remain in

continuous remission: Five-year follow-up of 300 patients

treated with fludarabine, cyclophosphamide, and rituximab

(FCR) as initial therapy of CLL (CS Tam; Abstract 7008)

Time: 14:15-14:30

Salvage therapy following failure or relapse after FCR

chemo-immunotherapy as initial treatment for chronic

lymphocytic leukemia (CLL) (MJ Keating; Abstract 7009)

Time: 14:30-14:45

M

M

M

M

M

Saturday

2 June

MabTheraM


14


Time: 13:00-16:00Venue: N Hall B1

Lung cancer I

Randomised, double-blind multicentre phase III study of

bevacizumab in combination with cisplatin and gemcitabine

in chemotherapy-naïve patients with advanced or recurrent

non-squamous non-small cell lung cancer (NSCLC):

BO17704 (C Manegold; Abstract LBA7514)

Time: 14:45-15:00



Breast cancer – local-regional and adjuvant therapy

Inflammatory and locally advanced breast cancer respond

similar to operable breast cancer to neoadjuvant

chemotherapy: Results from 278 patients with cT4a-d

tumors of the GeparTRIO trial (G Von Minckwitz;

Poster A1, Abstract 542)

Effect of monthly oral ibandronate on anastrozole-induced

bone loss during adjuvant treatment for breast cancer:

One-year results from the ARIBON study (JE Lester;

Poster A12, Abstract 553)

A pilot study of adjuvant bevacizumab after neoadjuvant

chemotherapy for high-risk breast cancer (EL Mayer;

Poster B6, Abstract 561)

Adjuvant (adj) bevacizumab (B) plus dose-dense (dd)

doxorubicin/cyclophosphamide (AC) followed by

nanoparticle albumin-bound paclitaxel (nab-p) in early

stage breast cancer (BC) patients (pts): Cardiac safety

(MN Dickler; Poster B12, Abstract 567)

A

A

B

X

A

Saturday

2 June

Avastin Xeloda BondronatBXA


15

A correlative study of cardiac biomarkers and left ventricular

ejection fraction (LVEF) from N9831, a phase III

randomized trial of chemotherapy and trastuzumab as

adjuvant therapy for HER2-positive breast cancer

(LA Kutteh; Poster C10, Abstract 579)

Pathologic complete response (pCR) following weekly

(wkly) paclitaxel (cremophor or albumin-bound) and

carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in

patients (pts) with doxorubicin/cyclophosphamide-resistant

(AC-Res) and AC-sensitive (AC-S) large and inflammatory

breast cancer (RS Mehta; Poster D8, Abstract 591)



Breast cancer - metastatic

Safety and efficacy of combined trastuzumab and CMF

therapy in women with metastatic breast cancer: EORTC

protocol 10995 (Z Neskovic-Konstantinovic; Poster G2,

Abstract 1040)

A phase I study of trastuzumab-MCC-DM1 (T-DM1),

a first-in-class HER2 antibody-drug conjugate (ADC),

in patients (pts) with HER2+ metastatic breast cancer (BC)

(M Beeram; Poster G4, Abstract 1042)

Preclinical testing of a novel regimen of capecitabine (C)

in combination with bevacizumab (B) and trastuzumab (T)

in a breast cancer xenograft model (TA Traina; Poster G11,

Abstract 1049)

Efficacy of oral vinorelbine (NVBo), capecitabine (X)

and trastuzumab (H) triple combination (NVBoXH) in

HER2-positive metastatic breast cancer (MBC): First results

of an international phase II trial (A Chan; Poster G14,

Abstract 1052)

H

A

H

H

A

H

Saturday

2 June

Herceptin Avastin AH

H

H


16

Phase II trial of nab-paclitaxel (nanoparticle albumin-

bound paclitaxel (ABX)) + capecitabine (XEL) in first-

line treatment of metastatic breast cancer (MBC)

(SG Bradley; Poster H1, Abstract 1053)

Trastuzumab (T) plus capecitabine (C) in heavily

pretreated patients (pts) with advanced breast cancer

(ABC) (R Bartsch; Poster H3, Abstract 1055)

Chemoprotection by VEGF: Rationale for combination

nab-paclitaxel and bevacizumab (V Trieu; Poster H12,

Abstract 1064)

Activity of trastuzumab (t) beyond disease progression

in HER2 over-expressing metastatic breast cancer (MBC)

(G Metro; Poster H14, Abstract 1066)

Clodronate compared to ibandronate breast cancer bone

metastases patient preference study (S Jagdev; Poster J2,

Abstract 1068)

Inter- and intra-country variations in the use of

trastuzumab in Norway, Spain and Sweden (N Wilking;

Poster J3, Abstract 1069)

Cost-effectiveness of HER2 testing and trastuzumab therapy

for metastatic breast cancer (MBC) patients in Sweden

(M Lidgren; Poster L8; Abstract 1088)

Capecitabine (X) monotherapy as first-line chemotherapy

(CT) for metastatic breast cancer (MBC): High efficacy

regardless of prior therapy (L Mauriac; Poster M1,

Abstract 1092)

Efficacy and safety of trastuzumab plus vinorelbine as

second-line treatment for women with HER2-positive

metastatic breast cancer beyond disease progression

(T Bachelot; Poster M3, Abstract 1094)

Administration of further chemotherapy (CT) after

capecitabine as first-line chemotherapy (CT) for metastatic

breast cancer (MBC) (M Debled; Poster M4, Abstract 1095)

X

H

X

H

H

B

H

A

H

X

Saturday

2 June

Xeloda Herceptin Avastin Bondronat BAHX

X


17

Efficacy of i.v. and oral ibandronate in bone metastases

breast cancer patients and some clinical aspects of

bisphosphonates studies: Clinical experience of one trial

center (M Lichinitser; Poster M5, Abstract 1096)

A retrospective review of breast cancer patients with central

nervous system metastasis treated with capecitabine

(M Kurt; Poster M7, Abstract 1098)

Bevacizumab and albumin-bound paclitaxel treatment

in metastatic breast cancer (JS Link; Poster M10,

Abstract 1101)

Randomized phase II trial of three dosing schedules of

nanoparticle albumin-bound paclitaxel with bevacizumab

as first-line therapy for HER2-negative metastatic breast

cancer: An initial interim safety report (AK Conlin;

Poster N2, Abstract 1104)

Renal safety of intravenous ibandronate 6mg infused over

15 or 60 minutes in patients with breast cancer and bone

metastases: A randomized, open-label study (R von Moos;

Poster P1, Abstract 1114)

POSTER DICUSSION SESSION


Gastrointestinal (colorectal) cancer

Bevacizumab (Bev) in combination with XELOX or

FOLFOX4: Updated efficacy results from XELOX-1/

NO16966, a randomized phase III trial in first-line metastatic

colorectal cancer (L Saltz; Poster 15, Abstract 4028)

Comparable safety and response rate with bevacizumab in

combination with capecitabine/oxaliplatin (CapOx/Bev)

versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC

(mCRC): A randomized phase II study of the AIO GI tumor

study group (WH Schmiegel; Poster 21, Abstract 4034)

A

A

B

A

A

X

B

Saturday

2 June

Bondronat Xeloda AvastinAXB


18

Association between exposure to bevacizumab (BV) beyond

first progression (BBP) and overall survival (OS) in patients

(pts) with metastatic colorectal cancer (mCRC): Results

from a large observational study (BRiTE) (A Grothey;

Poster 23, Abstract 4036)


Time: 15:00-18:15Venue: E Hall D2

Head and neck cancer

Final results of a phase II study of erlotinib, docetaxel and

cisplatin in patients with recurrent/metastatic head and neck

cancer (ES Kim; Abstract 6013)

Time: 17:30-17:45

CLINICAL SCIENCE SYMPOSIUM


Targeting breast cancer with monoclonal antibodiesand small molecules: beyond HER2

Objective response rate in a phase II multicenter trial of

pertuzumab (P), a HER2 dimerization inhibiting

monoclonal antibody, in combination with trastuzumab (T)

in patients (pts) with HER2-positive metastatic breast cancer

(MBC) which has progressed during treatment with T

(J Baselga; Abstract 1004)

Time: 17:30-17:45

H

T

A

Saturday

2 June

Avastin Tarceva Herceptin HTA


19



Developmental therapeutics: immunotherapy

Lumiliximab (anti-CD23 antibody) mediates apoptosis and

antitumor activity in chronic lymphocytic leukemia (CLL)

cells and CD23+ lymphoma cell lines (N Pathan; Poster E5,

Abstract 3039)



Developmental therapeutics: molecular therapeutics

A phase I dose escalation pharmacokinetic (PK) and

pharmacodynamic (PD) study of weekly and twice weekly

erlotinib in advanced stage solid malignancies (SK Chia;

Poster M2, Abstract 3594)



Lung cancer

Phase II study of erlotinib in chemo-naive women with

advanced pulmonary adenocarcinoma (D Jackman;

Poster P5, Abstract 7591)

Skin rash as surrogate marker of efficacy in patients with

non-small cell lung cancer treated with erlotinib (M Cobo;

Poster Q5, Abstract 7602)

Correlation of the EGFR gene mutation, gene amplification

and protein expression in non-small cell lung cancer with

clinical outcomes of erlotinib monotherapy: An exploratory

analysis of biomarkers by the Korean Cancer Study Group

(M-J Ahn; Poster Q11, Abstract 7608)

T

T

T

T

M

Sunday

3 June

MabThera TarcevaTM


20

A phase II study of erlotinib (E) and bevacizumab (B)

in patients (pts) with previously untreated stage IIIB/IV

non-small cell lung cancer (NSCLC) (HJ Groen; Poster S6,

Abstract 7625)

Erlotinib for first line treatment in unselected patients (p)

with advanced or metastatic non-small cell lung carcinoma

(NSCLC) (U Jimenez; Poster T9, Abstract 7639)

Erlotinib in non-small cell lung cancer (NSCLC): Interim

safety analysis of the TRUST study (U Gatzemeier;

Poster U4, Abstract 7645)

Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed

in the treatment of refractory non-small cell lung cancer

(NSCLC) (J Carlson; Poster X1, Abstract 7664)

Biomarker analysis from TRUST, a trial of erlotinib in non-

small cell lung cancer (NSCLC) (C-P Schneider; Poster Y3,

Abstract 7674)

Randomized phase II study of erlotinib alone and in

combination with bortezomib in previously treated

advanced non-small cell lung cancer (NSCLC) (TJ Lynch;

Poster Z1, Abstract 7680)



Breast cancer – metastatic

Phase III trial of ixabepilone plus capecitabine compared to

capecitabine alone in patients with metastatic breast cancer

(MBC) previously treated or resistant to an anthracycline

and resistant to taxanes (LT Vahdat; Abstract 1006)

Time: 09:15-09:30

X

T

T

T

T

T

T

Sunday

3 June

Tarceva Xeloda XT


21

BCIRG 007: First overall survival analysis of randomized

phase III trial of trastuzumab plus docetaxel with or without

carboplatin as first line therapy in HER2 amplified

metastatic breast cancer (MBC) (MD Pegram;

Abstract LBA1008)

Time: 09:45-10:00

Safety and efficacy of capecitabine (C) plus bevacizumab (B)

as first-line in metastatic breast cancer (G Sledge;

Abstract 1013)

Time: 11:30-11:45


Time: 09:30-12:30Venue: E354b

Lymphoma

Revalidation of FLIPI in patients with follicular lymphoma

(FL) registered in the F2 study and treated upfront with

immunochemotherapy (M Federico; Abstract 8008)

Time: 09:30-09:45

Long-term results of the GELA study comparing R-CHOP

and CHOP chemotherapy in older patients with diffuse

large B-cell lymphoma show good survival in poor-risk

patients (B Coiffier; Abstract 8009)

Time: 09:45-10:00

Rituximab compared to observation after high-dose

consolidative first-line chemotherapy (HDC) with

autologous stem cell transplantation in poor-risk diffuse

large B-cell lymphoma: Updated results of the LNH98-B3

GELA study (C Haioun; Abstract 8012)

Time: 10:45-11:00

M

M

M

A

H

Sunday

3 June

Herceptin Avastin Xeloda MabThera MXAH

X


22


Time: 13:00-16:00Venue: E354b

Myeloma

Long-term responses to thalidomide and rituximab in

Waldenstrom's macroglobulinemia (JD Soumerai;

Abstract 8017)

Time: 13:00-13:15



Pediatric cancer

ITCC phase I study of erlotinib as single agent in children

with refractory and relapsed malignant brain tumors and in

combination with irradiation in newly diagnosed brain stem

glioma (B Geoerger; Poster Z8, Abstract 9556)

POSTER DISCUSSION SESSION



Neoadjuvant trastuzumab in locally advanced breast cancer

(NOAH): Antitumour and safety analysis (L Gianni;



Time: 14:00-18:00 [discussion 17:00-18:00]Venue: S102a [S100b]

Developmental therapeutics: immunotherapy

A phase II trial of trastuzumab and low dose interleukin-2 in

patients with metastatic breast cancer who have previously

failed trastuzumab (A Mani; Poster 19, Abstract 3028)

H

H

T

M

Sunday

3 June

MabThera Tarceva Herceptin HTM


23

CLINICAL SCIENCE SYMPOSIUM

Time: 16:30-18:00Venue: E354b

Improving survival in follicular lymphoma:integrating new therapy

Prospective, multicenter, randomized GITMO-IIL trial

comparing intensive (R-HDS) to conventional

chemoimmunotherapy (CHOP-R) in high-risk follicular

lymphoma (FL) at diagnosis (M Ladetto; Abstract 8006)

Time: 17:30-17:45

M

Sunday

3 June

MabTheraM


24



Gastrointestinal (colorectal) cancer

Phase I/II study of neoadjuvant bevacizumab with radiation

therapy and 5-fluorouracil in patients with rectal cancer:

initial results (C Willett; Poster A3, Abstract 4041)

Effectiveness of neoadjuvant chemotherapy including

bevacizumab in patients with resectable colorectal cancer

liver metastases (B Gruenberger; Poster D1, Abstract 4060)

Bevacizumab plus XELOX as neoadjuvant therapy for

patients with potentially curable metastatic colorectal cancer

(T Gruenberger; Poster D5, Abstract 4064)

Phase IV study of first-line bevacizumab plus irinotecan and

infusional 5-FU/LV in patients with metastatic colorectal

cancer: AVIRI (AF Sobrero; Poster E2, Abstract 4068)

Preliminary efficacy of bevacizumab with first-line

FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC:

First BEATrial (A Kretzschmar; Poster E6, Abstract 4072)

Magnitude of progression-free survival (PFS) improvement

and treatment (Tx) duration in metastatic colorectal cancer

(mCRC) for bevacizumab (BV) in combination with

oxaliplatin-containing regimens: An analysis of two phase III

studies (BJ Giantonio; Poster E7, Abstract 4073)

A comparison of medical resource use for 4 chemotherapy

regimens as first-line treatment for metastatic colorectal

cancer (MCRC): XELOX vs. FOLFOX4 ± bevacizumab (A)

(W Scheithauer; Poster J4, Abstract 4098)

A

A

A

A

A

A

A

Monday

4 June

AvastinA


25



Gastrointestinal (noncolorectal) cancer

A phase I study of erlotinib, bevacizumab and gemcitabine

in patients with advanced pancreatic cancer

(C Gomez-Martin; Poster BB2, Abstract 4611)


Time: 08:00-12:00 [discussion 11:00-12:00]Venue: E451a [E354b]

Leukemia, myelodysplasia and transplantation

Beta-2 microglobulin (B2M) is an independent prognostic

factor for clinical outcomes in patients with CLL treated

with frontline fludarabine, cyclophosphamide, and

rituximab (FCR) regardless of age, creatinine clearance

(CrCl) (AM Tsimberidou; Poster 22, Abstract 7034)


Time: 09:00-12:00Venue: E Hall D1


Updated results of the combined analysis of NCCTG N9831

and NSABP B-31 adjuvant chemotherapy with/without

trastuzumab in patients with HER2-positive breast cancer

(E Perez; Abstract 512)

Time: 09:00-09:15

Five year update of cardiac dysfunction on NSABP B-31,

a randomized trial of sequential doxorubicin/

cyclophosphamide (AC) paclitaxel (T) vs. AC T with

trastuzumab (H) (P Rastogi; Abstract LBA513)

Time: 09:15-09:30

H

H

M

T

Monday

4 June

Tarceva MabThera Herceptin HMT


26

SPECIAL SESSION


Monday plenary session

A randomized, controlled, double-blind phase III study

(AVOREN) of bevacizumab/interferon-�2a vs

placebo/interferon-�2a as first-line therapy in metastatic

renal cell carcinoma (B Escudier; Abstract 3)

Time: 14:30-14:45


Time: 14:00-18:00 [discussion 17:00-18:00]Venue: E451a [E354b]

Lymphoma and plasma cell disorders

A phase I/II study of lenalidomide (Len) in combination

with rituximab (R) in relapsed/refractory mantle cell

lymphoma (MCL) with early evidence of efficacy

(M Wang; Poster 5, Abstact 8030)

Bendamustine and rituximab (BR) are effective in the

treatment of relapsed or refractory indolent and mantle-cell

lymphomas: Long-term follow-up of a phase II study

(MJ Rummel; Poster 9, Abstract 8034)

Efficacy and toxicity of dose-adjusted EPOCH-rituximab

in adults with newly diagnosed Burkitt lymphoma

(K Dunleavy; Poster 10, Abstract 8035)

R-Dhaox, high dose chemotherapy (HDC) and rituximab

maintenance as salvage treatment in relapsed/refractory

(R/R) follicular (F) and mantle cells (MC) lymphomas

(NHL) (M Rupolo; Poster 11, Abstract 8036)

M

M

M

M

A

Monday

4 June

Avastin MabTheraMA


27

Incidence and risk factors for central nervous system relapse

in patients with diffuse large B-cell lymphoma: The impact

of the addition of rituximab to CHOP chemotherapy

(D Villa; Poster 12, Abstract 8037)

Effect of addition of rituximab to CHOP on survival of

patients in both the GCB and non-GCB subgroups of diffuse

large B-cell lymphoma (K Fu; Poster 15, Abstract 8040)

Rituximab induces long-term remissions in patients with

HIV-associated multicentric Castleman's disease (M Bower;


M

M

M

Monday

4 June

MabTheraM


28


Time: 08:00-12:00 [discussion 11:00-12:00]Venue: E451a [E354a]

Lung cancer II

Updated molecular analyses of exons 19 and 21 of the

epidermal growth factor receptor (EGFR) gene and codons

12 and 13 of the KRAS gene in non-small cell lung cancer

(NSCLC) patients treated with erlotinib in National Cancer

Institute of Cancer (FA Shepherd; Poster 20, Abstract 7571)

T

Tuesday

5 June

TarcevaT


29


Chicago Marriott DowntownMagnificent Mile540 North Michigan Avenue,Chicago, IL 60611 Tel: 312 836 0100; Fax: 312 836 6139www.marriott.comBreakfast: Ventoso, 06:00-11:00

Four Points by Sheraton630 North Rush Street,Chicago, IL 60611Tel: 312 981 6600; Fax: 312 981 6622www.fourpointschicago.comBreakfast: Chicago's Room,4th floor,Mon-Fri 06:30-10:00;Sat/Sun 07:00-10:30

Four Seasons Hotel Chicago120 East Delaware Place,Chicago, IL 60611Tel: 312 280 8800; Fax: 312 280 1748www.fourseasons.comBreakfast: Seasons, 06:30-10:00

Hilton Chicago720 South Michigan Avenue,Chicago, IL 60605Tel: 312 922 4400; Fax: 312 922 5240www1.hilton.comBreakfast: The Pavilion,Mon-Fri 05:30-11:00;Sat 05:30-12:00; Sun 05:30-14:00

Hotel Orrington1710 Orrington Avenue,Evanston, IL 60201Tel: 847 866 8700; Fax: 847 866 8724www.hotelorrington.comBreakfast: The Globe Café,1st floor, 06:00-09:00

House of Blues Hotel333 North Dearborn Street,Chicago, IL 60610Tel: 312 245 0333; Fax: 312 923 2458www.houseofblueshotel.comBreakfast: Bin36,Mon-Fri 06:30-10:00;Sat/Sun 07:00-12:00

Hyatt Regency Chicago151 East Wacker Drive,Chicago, IL 60601Tel: 312 565 1234; Fax: 312 239 4414www.chicagoregency.hyatt.comBreakfast: The Bistro at 151,East Tower, Green Level, 06:00-11:00

Hyatt Regency McCormick Place2233 South Martin Luther KingDrive, Chicago, IL 60616Tel: 312 567 1234; Fax: 312 528 4000www.mccormickplace.hyatt.comBreakfast: Shor, Grand Concourse,06:30-11:00

Palmer House Hilton17 East Monroe Street,Chicago, IL 60603Tel: 312 726 7500; Fax: 312 917 1707www1.hilton.comBreakfast: The Big Downtown,lower level, 06:30-10:00

Ritz-Carlton Chicago160 East Pearson Street,Chicago, IL 60611Tel: 312 266 1000; Fax: 312 266 1194www.fourseasons.comBreakfast: The Café, 06:30-11:00

Whitehall Hotel105 East Delaware Place,Chicago, IL 60611Tel: 312 944 6300; Fax: 312 944 8552www.thewhitehallhotel.comBreakfast: Fornetto Mei,1st floor, 07:00-11:00

30

Hotels


31

S Martin

Luther King Dr

Navy Pier

W Division St

W Chicago Ave

W Ontario

W Ohio

W Randolph St

W Jackson Blvd

W Roosevelt Rd

S State st

Colu

mbu

s Dr

S Mich

igan A

ve

N State st

W Cermak Rd

Congress Parkway

Lake Shore Drive

E Balbo Dr

W Wacker Dr

E Wacker Dr

Hyatt Regency McCormick

McCormick Place

Palmer House

Hyatt Regency

Four Points Sheraton

House of Blues

Ritz Carlton

WhitehallFour Seasons

Marriot

Hilton

ChicagoDowntown

LakeMichigan

MortonGrove

Lincolnwood

Niles

Golf

Eden

s Expy W

Edens Expy W

Kennedy Expy W

Kennedy Expy W

Eisenhower Expy W Eisenhower Expy W

Chicago

NearNorth Side

LincolnPark

Summerdale

Uptown

RogersPark

Oakton

LincolnParkElmwood

Park

OakPark

Skokie

Evanston Hotel Orrington

Map


32

Notes


33

Notes


34

Notes


F. Hoffmann-La Roche Ltd

CH-4070 Basel

Switzerland


McCormick Place Chicago, IL, USA

Documents

Transcript of McCormick Place Chicago, IL, USA